Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
GLYC Stock Forecast 2026-2027
$15.69
Current Price
$1.01B
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to GLYC Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
GLYC Price Momentum
-9.5%
1 Week Change
-13.8%
1 Month Change
+20.5%
1 Year Change
+32.3%
Year-to-Date Change
-42.8%
From 52W High of $27.41
+79.9%
From 52W Low of $8.72
📊 TOP ANALYST CALLS
Did GLYC Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if GlycoMimetics is one of their latest high-conviction picks.
Latest GLYC Stock Price Targets & Analyst Predictions
GLYC has shown a year-to-date change of 32.3% and a 1-year change of 20.5%, reflecting upward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for GLYC. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
GLYC Analyst Ratings
1
Buy
0
Hold
0
Sell
GLYC Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $15.69
Latest GLYC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for GLYC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 21, 2025 | Cantor Fitzgerald | Eric Schmidt | Overweight | Initiates | $N/A |
| Jul 26, 2024 | TD Cowen | Boris Peaker | Hold | Downgrade | $N/A |
| Jun 4, 2024 | HC Wainwright & Co. | Edward White | Neutral | Reiterates | $N/A |
| May 6, 2024 | HC Wainwright & Co. | Edward White | Neutral | Downgrade | $N/A |
| Mar 27, 2024 | HC Wainwright & Co. | Edward White | Buy | Maintains | $8.00 |
| Dec 22, 2023 | Capital One | Zegbeh Jallah | Overweight | Initiates | $12.00 |
| Aug 3, 2023 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $8.00 |
| Jun 15, 2023 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $8.00 |
| May 4, 2023 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $8.00 |
| Mar 30, 2023 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $8.00 |
| Feb 16, 2023 | HC Wainwright & Co. | Edward White | Buy | Maintains | $8.00 |
| Aug 4, 2022 | HC Wainwright & Co. | Edward White | Buy | Maintains | $13.00 |
| Nov 12, 2021 | Jefferies | Roger Song | Buy | Upgrade | $4.00 |
| Dec 8, 2020 | Roth Capital | Buy | Maintains | $15.00 | |
| Jul 31, 2020 | HC Wainwright & Co. | Buy | Maintains | $15.00 | |
| Mar 2, 2020 | H.C. Wainwright | Buy | Reiterates | $N/A | |
| Mar 2, 2020 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $16.00 |
| Nov 14, 2019 | Roth Capital | Buy | Initiates | $N/A | |
| Aug 5, 2019 | Jefferies | Hold | Downgrade | $N/A | |
| Aug 5, 2019 | SunTrust Robinson Humphrey | Hold | Downgrade | $5.00 |
Crescent Biopharma, Inc. (GLYC) Competitors
The following stocks are similar to GlycoMimetics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
GLYC
GlycoMimetics
mkt cap
1.08B
Crescent Biopharma, Inc. (GLYC) Financial Data
Valuation Metrics
Market Cap
$1.01B
Enterprise Value
$1.00B
P/E Ratio
-26.6x
PEG Ratio
0.3x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
EPS Growth
N/A
Financial Health
Cash/Price Ratio
N/A
Current Ratio
2.3x
Debt/Equity
0.0x
ROE
-712.9%
ROA
-341.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Crescent Biopharma, Inc. (GLYC) Business Model
About Crescent Biopharma, Inc.
What They Do
Develops innovative therapies for niche diseases.
Business Model
Crescent Biopharma generates revenue through the development and commercialization of novel drug therapies aimed at addressing unmet medical needs. The company focuses on advancing its drug candidates through clinical trials, ultimately seeking to bring them to market for patient use. This model relies on successful development outcomes and partnerships within the pharmaceutical industry.
Additional Information
Crescent Biopharma's commitment to addressing rare diseases positions it uniquely in the biopharmaceutical sector. Its listing on the Frankfurt Stock Exchange provides visibility for investors and facilitates tracking of its financial performance as the company progresses with its clinical pipeline and therapeutic innovations.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
55
CEO
Mr. Joshua T. Brumm
Country
United States
IPO Year
2014
Website
crescentbiopharma.comCrescent Biopharma, Inc. (GLYC) Latest News & Analysis
Latest News
GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals
1 year ago
Quick Summary
GlycoMimetics, Inc. stockholders approved the merger with Crescent Biopharma and related proposals, including a reverse stock split, during a special meeting on June 5, 2025.
Why It Matters
GlycoMimetics' stockholders approved a merger with Crescent Biopharma and a reverse stock split, which could impact share value and liquidity, influencing investor sentiment and market dynamics.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Crescent Biopharma will present at the Jefferies Global Healthcare Conference on June 5, 2025, focusing on its development of precision-engineered molecules for solid tumors.
Why It Matters
Crescent Biopharma's presentation at a major healthcare conference could lead to increased visibility, potential partnerships, or investments, impacting its valuation and market sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Kahn Swick & Foti, LLC is investigating the proposed merger between GlycoMimetics, Inc. (GLYC) and Crescent Biopharma, Inc., focusing on the adequacy of the merger process for GlycoMimetics' shareholders.
Why It Matters
Concerns over the merger's fairness and adequacy can impact GlycoMimetics' stock price and investor confidence, potentially leading to volatility and shifts in market sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Crescent Biopharma has appointed David Lubner, an industry veteran with 30 years of experience in finance and operations, to its board of directors as of April 28, 2025.
Why It Matters
David Lubner's appointment signals strong leadership and expertise, potentially enhancing Crescent Biopharma's strategic direction and operational efficiency, which may boost investor confidence and company performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Jonathan McNeill, M.D., has been appointed as President and Chief Operating Officer, succeeding Ellie Im, M.D.
Why It Matters
Leadership changes can impact company strategy and performance, influencing investor confidence and stock value. Monitoring new executives' backgrounds and their plans is crucial for future outlook.
Source: GlobeNewsWire
Market Sentiment:
Neutral
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX and GLYC on Behalf of Shareholders
1 year ago
Quick Summary
Halper Sadeh LLC is investigating Chimerix, Inc. (NASDAQ: CMRX) for potential securities law violations related to its sale to Jazz Pharmaceuticals for $8.55 per share.
Why It Matters
The investigation into Chimerix's sale may indicate potential legal issues, affecting the deal's stability and share value, which could impact investor decisions and market sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About GLYC Stock
What is Crescent Biopharma, Inc.'s (GLYC) stock forecast for 2027?
Analyst forecasts for Crescent Biopharma, Inc. (GLYC) are not currently available. The stock is trading at $15.69.
Is GLYC stock a good investment in 2027?
According to current analyst ratings, GLYC has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $15.69. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for GLYC stock?
Price predictions from Wall Street analysts for GLYC are not currently available. The stock is trading at $15.69.
What is Crescent Biopharma, Inc.'s business model?
Crescent Biopharma generates revenue through the development and commercialization of novel drug therapies aimed at addressing unmet medical needs. The company focuses on advancing its drug candidates through clinical trials, ultimately seeking to bring them to market for patient use. This model relies on successful development outcomes and partnerships within the pharmaceutical industry.
What is the highest forecasted price for GLYC Crescent Biopharma, Inc.?
Price targets from Wall Street analysts for GLYC are not currently available. The stock is trading at $15.69.
What is the lowest forecasted price for GLYC Crescent Biopharma, Inc.?
Price targets from Wall Street analysts for GLYC are not currently available. The stock is trading at $15.69.
What is the overall GLYC consensus from analysts for Crescent Biopharma, Inc.?
The overall analyst consensus for GLYC is bullish. Out of 7 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell.
How accurate are GLYC stock price projections?
Stock price projections, including those for Crescent Biopharma, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 16, 2026 6:36 PM UTC